JO3279B1 - مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز - Google Patents
مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيزInfo
- Publication number
- JO3279B1 JO3279B1 JOP/2014/0103A JOP20140103A JO3279B1 JO 3279 B1 JO3279 B1 JO 3279B1 JO P20140103 A JOP20140103 A JO P20140103A JO 3279 B1 JO3279 B1 JO 3279B1
- Authority
- JO
- Jordan
- Prior art keywords
- phosphoinositide
- quinazolin
- pyrazolo
- pyrimidin
- hydroxyphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
يتعلق الاختراع الحالي في طياته بمركب الصيغة (I) وبتركيبات إتحادية تتضمن نفس المركب وباستخدام المركبات وتركيبات إتحادية من المركبات في العلاج، على سبيل المثال في علاج الأمراض الالتهابية، وبشكل أخص مرض التهاب الجهاز التنفسي. يمتد الاختراع أيضا لطرق صناعة المركبات المذكورة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13275070 | 2013-03-15 | ||
EP13193372 | 2013-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3279B1 true JO3279B1 (ar) | 2018-09-16 |
Family
ID=50349644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0103A JO3279B1 (ar) | 2013-03-15 | 2014-03-13 | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
Country Status (24)
Country | Link |
---|---|
US (2) | US9745306B2 (ar) |
EP (1) | EP2970293B1 (ar) |
JP (1) | JP6353856B2 (ar) |
KR (1) | KR20150127607A (ar) |
CN (1) | CN105229007B (ar) |
AU (1) | AU2014229768B2 (ar) |
BR (1) | BR112015019754A8 (ar) |
CA (1) | CA2899812A1 (ar) |
CL (1) | CL2015002606A1 (ar) |
EA (1) | EA029218B1 (ar) |
ES (1) | ES2640624T3 (ar) |
GT (1) | GT201500218A (ar) |
HK (1) | HK1214591A1 (ar) |
IL (1) | IL240061A0 (ar) |
JO (1) | JO3279B1 (ar) |
MX (1) | MX2015012091A (ar) |
NI (1) | NI201500134A (ar) |
PE (1) | PE20151653A1 (ar) |
PH (1) | PH12015501836A1 (ar) |
SG (1) | SG11201505928YA (ar) |
TW (1) | TW201522341A (ar) |
UA (1) | UA116002C2 (ar) |
UY (1) | UY35446A (ar) |
WO (1) | WO2014140597A1 (ar) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198279B2 (en) | 2007-12-19 | 2012-06-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use |
AU2011209586B2 (en) | 2010-02-01 | 2016-01-21 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
DK2945939T3 (da) | 2013-01-15 | 2020-03-23 | Incyte Holdings Corp | Thiazolcarboxamider og pyridincarboxamidforbindelser anvendelige som pim-kinaseinhibitorer |
AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
UA115296C2 (uk) | 2014-07-04 | 2017-10-10 | Люпін Лімітед | Хінолізинонові похідні як інгібітори pi3k |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140938B1 (en) | 1999-01-11 | 2003-08-27 | Princeton University | High affinity inhibitors for target validation and uses thereof |
SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
DE60144322D1 (de) | 2000-04-27 | 2011-05-12 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JP2005509594A (ja) | 2001-07-13 | 2005-04-14 | バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド | Nadシンテターゼ阻害剤およびその使用 |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
AU2003301662A1 (en) | 2002-10-21 | 2004-05-13 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
EP1604981A4 (en) | 2003-03-14 | 2008-12-24 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
EP1661879A4 (en) | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF |
WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
US20050239809A1 (en) | 2004-01-08 | 2005-10-27 | Watts Stephanie W | Methods for treating and preventing hypertension and hypertension-related disorders |
CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
ES2605792T3 (es) * | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana |
JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
CA2569406A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
PE20060598A1 (es) | 2004-09-13 | 2006-08-21 | Ono Pharmaceutical Co | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
EP1885356A2 (en) | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
US20070063319A1 (en) | 2005-09-19 | 2007-03-22 | Bohumil Lojek | Film stack and method for fabricating the same |
EP2004654B1 (en) | 2006-04-04 | 2013-05-22 | The Regents of the University of California | Pyrazolopyrimidine derivatives for use as kinase antagonists |
CN101448505A (zh) * | 2006-04-04 | 2009-06-03 | 加利福尼亚大学董事会 | Pi3激酶拮抗剂 |
CN101506198A (zh) | 2006-06-29 | 2009-08-12 | 先灵公司 | 取代的双环和三环凝血酶受体拮抗剂 |
CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
KR101653842B1 (ko) | 2008-01-04 | 2016-09-02 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US20110269779A1 (en) | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
CA2745280A1 (en) | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
US8658648B2 (en) | 2008-12-05 | 2014-02-25 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
BR112012002331A2 (pt) | 2009-08-05 | 2019-09-24 | Versitech Ltd | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica |
GB0918249D0 (en) * | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
UY33337A (es) * | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
LT2834244T (lt) | 2012-03-13 | 2016-11-10 | Respivert Limited | Kristalinės pi3 kinazės slopikliai |
US9227977B2 (en) * | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
-
2014
- 2014-03-13 TW TW103108912A patent/TW201522341A/zh unknown
- 2014-03-13 JO JOP/2014/0103A patent/JO3279B1/ar active
- 2014-03-14 US US14/777,021 patent/US9745306B2/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020157023823A patent/KR20150127607A/ko not_active Application Discontinuation
- 2014-03-14 UY UY0001035446A patent/UY35446A/es unknown
- 2014-03-14 PE PE2015001926A patent/PE20151653A1/es not_active Application Discontinuation
- 2014-03-14 UA UAA201507682A patent/UA116002C2/uk unknown
- 2014-03-14 EA EA201591804A patent/EA029218B1/ru not_active IP Right Cessation
- 2014-03-14 CN CN201480015955.2A patent/CN105229007B/zh not_active Expired - Fee Related
- 2014-03-14 EP EP14712334.3A patent/EP2970293B1/en active Active
- 2014-03-14 ES ES14712334.3T patent/ES2640624T3/es active Active
- 2014-03-14 WO PCT/GB2014/050770 patent/WO2014140597A1/en active Application Filing
- 2014-03-14 BR BR112015019754A patent/BR112015019754A8/pt not_active IP Right Cessation
- 2014-03-14 SG SG11201505928YA patent/SG11201505928YA/en unknown
- 2014-03-14 JP JP2015562319A patent/JP6353856B2/ja not_active Expired - Fee Related
- 2014-03-14 CA CA2899812A patent/CA2899812A1/en not_active Abandoned
- 2014-03-14 AU AU2014229768A patent/AU2014229768B2/en not_active Ceased
- 2014-03-14 MX MX2015012091A patent/MX2015012091A/es unknown
-
2015
- 2015-07-21 IL IL240061A patent/IL240061A0/en unknown
- 2015-08-04 GT GT201500218A patent/GT201500218A/es unknown
- 2015-08-20 PH PH12015501836A patent/PH12015501836A1/en unknown
- 2015-09-11 CL CL2015002606A patent/CL2015002606A1/es unknown
- 2015-09-11 NI NI201500134A patent/NI201500134A/es unknown
-
2016
- 2016-03-03 HK HK16102451.0A patent/HK1214591A1/zh not_active IP Right Cessation
-
2017
- 2017-07-27 US US15/661,279 patent/US20170334919A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014140597A1 (en) | 2014-09-18 |
KR20150127607A (ko) | 2015-11-17 |
EP2970293A1 (en) | 2016-01-20 |
AU2014229768A1 (en) | 2015-08-06 |
SG11201505928YA (en) | 2015-09-29 |
US9745306B2 (en) | 2017-08-29 |
CA2899812A1 (en) | 2014-09-18 |
US20170334919A1 (en) | 2017-11-23 |
CN105229007B (zh) | 2017-08-25 |
JP2016510802A (ja) | 2016-04-11 |
US20160039826A1 (en) | 2016-02-11 |
GT201500218A (es) | 2017-09-21 |
PE20151653A1 (es) | 2015-11-12 |
EA029218B1 (ru) | 2018-02-28 |
AU2014229768B2 (en) | 2018-01-04 |
EP2970293B1 (en) | 2017-06-14 |
EA201591804A1 (ru) | 2016-01-29 |
UY35446A (es) | 2014-09-30 |
MX2015012091A (es) | 2016-04-15 |
NI201500134A (es) | 2016-01-06 |
CL2015002606A1 (es) | 2016-03-04 |
UA116002C2 (uk) | 2018-01-25 |
PH12015501836A1 (en) | 2015-11-09 |
ES2640624T3 (es) | 2017-11-03 |
BR112015019754A2 (pt) | 2017-07-18 |
JP6353856B2 (ja) | 2018-07-04 |
IL240061A0 (en) | 2015-09-24 |
CN105229007A (zh) | 2016-01-06 |
TW201522341A (zh) | 2015-06-16 |
BR112015019754A8 (pt) | 2019-11-12 |
HK1214591A1 (zh) | 2016-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3279B1 (ar) | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز | |
MX346336B (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa. | |
NZ764151A (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
PH12015502563A1 (en) | Bipyrazole derivatives as jak inhibitors | |
EP4233869A3 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
MX2016007371A (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
MX2019011954A (es) | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. | |
MD4666B1 (ro) | Inhibitori ai Syk | |
UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
NZ728660A (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor | |
CR20150391A (es) | Derivados 2-((4-amino-3-(3-fluoro-5-hidroxifenilo)-1h-pirazolo[3,4-d]pirimidin-1-il)metilo)-3-(2-(trifluoro-metilo)bencilo)quinazolin-4(3h)-ona y su uso como inhibidores de quinasa-3 fosfoinositida | |
TH165755A (th) | อนุพันธ์ 2-((4-อะมิโน-3-(3-ฟลูออโร-5-ไฮดรอกซีเฟนิล)-1h-ไพราโซโล[3,4-d]ไพริมิดีน-1-อิล)เมทธิล)-3-(2-ไตรฟลูออโรเมทธิล)เบนซิล)ควินาโซลิน-4(3h)-โอน และการใช้สารเหล่านี้เป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3- ไคเนส | |
TH165755B (th) | อนุพันธ์ 2-((4-อะมิโน-3-(3-ฟลูออโร-5-ไฮดรอกซีเฟนิล)-1h-ไพราโซโล[3,4-d]ไพริมิดีน-1-อิล)เมทธิล)-3-(2-ไตรฟลูออโรเมทธิล)เบนซิล)ควินาโซลิน-4(3h)-โอน และการใช้สารเหล่านี้เป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3- ไคเนส | |
TN2010000530A1 (en) | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | |
GEP201706680B (en) | Catechol o-methyltransferase activity inhibiting compounds | |
TR201901937T4 (tr) | 8-metil-1-fenil-imidazol[1,5-a]pirazin bileşikleri. |